Therapeutics, or coming up with next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments.
- Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community.
- Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making.
- The fund is structured to be S/EIS compliant providing income, inheritance and capital gains tax breaks for UK tax payers.
EIS tax relief is very attractive for UK tax payers
You invest £50k
EIS gives you £15k tax relief from HMRC
EIS gives you £25k tax relief from HMRC
Investment now worth £100k
£50k profit
income tax relief £15k
performance incentive £10k
net profit £55k
Investment still worth £50k
£0 profit
income tax relief £15k
performance incentive £0
net profit £15k
Investment now worth £0
£50k loss
income tax relief £15k
loss relief £15,750 *
performance incentive £0
capital loss £19,250
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
*Tax relief depends on an individual’s circumstances and may change in the future.
The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences amongst others which has led to higher potential exit valuations. The fund will help widen the community of investors that will help expand early stage research in the UK.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
- o2h Ventures Portfolio Company ViaNautis Enters Strategic Collaboration Agreement with Eli Lilly to Accelerate Genetic Medicine Development 30 October, 2024
- o2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024 9 August, 2024
- Proud Partner of the 30th Anniversary Event by EISA, celebrating three decades of Enterprise Investment Schemes (EIS) 6 August, 2024